I have more than 7 years experience investing in commodities and hard assets such as gold and silver miners, exploration companies, oil and gas producers, MLPs, and various other sectors.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
I am an early career scientist, engineer and entrepreneur working at a technology-stage startup (indeeTx.com).
I got started in July 2009 with average annual returns of 15.5% and 28.2% across two portfolios last calculated via XIRR and verified in March 2015. These calculations are inclusive of all stock market gains and losses for that period of time -- not just the choice ones.
Articles reflect my own decisions, but are not necessarily timed with trades. If you like my opinion do your own research and check mine -- your decisions are your own.
Additional information is published on StockViews (stockviews.com/users/2151), which measures performance relative to the S&P 500.
If you like this work and are seeking private research please make me an offer.
To follow me click the "Follow" button! (Easy right?) Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, software engineering, drumming, video games (developing and playing) and astronomy.
CEO of StockDotGenie.Com, a Technical Analysis (TA) charting platform targeted at new and novice traders who want to incorporate TA into their trading skills, but without taking years to learn and master the finer points.
YouTube Video on StockDotGenie: https://www.youtube.com/watch?v=kK1_x3Czuso
The educational website that supports the trading site is a practical and fundamental base for new traders to obtain an appreciation of both TA and the importance of correctly managing risk. My major at Missouri Western State Univ. was Computer Science. Beginning in 1989 I was the research director of a non-profit clinical research foundation then called Search Alliance. Our research focus included vaccines and antivirals. I subsequently started BioLogic, a consulting firm that focused on partnering emerging biotech’s with large Pharmaceuticals. BioLogic was instrumental in obtaining large pharmaceutical deals for the biotech's we represented. I invest in stocks utilizing every shred of information that technical, fundamental, human, social and internet sciences can provide. The more you know about a companies products, services, customers and investors, the greater your chances of being on the right side of a trade. "There are lots of shortcuts to losing money." Email: firstname.lastname@example.org
Lowenthal Capital Partners is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Law School.
Jennifer's areas of expertise include energy trends —their economic and geopolitical implications—and resource sustainability issues. Other interests include shale oil and natural gas, climate change, green and efficient infrastructure, China, India, and the energy-water nexus.
Her work has been published in various academic, policy and business publications such as Far Eastern Economic Review, Economist Intelligence Unit’s Executive Briefing, Journal of Structured Finance, Lloyd's List, D CEO, Energy Trends Insider, Financial Sense, and many others. She has been interviewed for numerous radio broadcasts and news stories, and presented her work at various conferences. From Dec 2010 to April 2013, she was the CEO/President of a global affairs organization focused on cutting edge trends. She organized and moderated panels on global gas, energy security, energy infrastructure finance, and urban development.
She has a master's degree from London School of Economics, and bachelor's in finance/marketing. She is principal of Concept Elemental, a strategic communications consultancy focusing on knowledge work, and includes over fifteen years of financial services industry work. She works with a top University, "translating" cutting edge research as well.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
David Zanoni is ranked in the top 1% of blogging analysts on Tipranks.com for performance and accuracy. He focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. David is a graduate of Rutgers University with a B.S. in Management. He is an independent long term investor of quality stocks and uses options for strategy. David believes in the power of innovation, capitalism, and the characteristics of the American spirit: intellect, fortitude, and adaptability to lead our country and the world to growing prosperity. His wants to help make people money by investing in high-quality growth stocks.
Livio has over a decade of investment experience with venture resource and clean technology companies. He has assisted in raising capital, running IR campaigns, and has spent 8 years in business development roles with several venture technology companies. Livio is a passive investor in Canadian mining and technology companies, with a focus on clean technologies and “green” resources. Livio has specific interest in the lithium supply chain and emerging energy storage markets.
Livio is dedicated to educating young investors about the benefits of investing in dividend stocks over the long term.
I manage my investments personally. I spend a couple hours per week reading articles and research on each security I own. I am not a professional by any stretch of the imagination, but enjoy reading about ideas people have. I try to put articles out that appeal to both the beginning investor as well as the seasoned veteran. I hope you enjoy reading my articles and will take the time to comment on them.
I have spent all 10+ years of my professional career in the genetic laboratory space both on the research and clinical side. I obtained my undergraduate degree in Biology and Chemistry with an emphasis on Molecular Genetics and Biochemistry from the University of Wisconsin-Stevens Point. In 2013 I received my MBA from Cardinal Stritch University.
I started following the stock market in 2007 and have found that I really have a passion for learning and trying to help individuals understand complicated topics. After getting my feet wet in an investment club and personal investments I decided to share my ideas on Seeking Alpha as I enjoy talking stocks with anyone that will listen. Additionally I feel I have some interesting perspectives to offer.
I have been investing in the stock market as a personal investor for approximately ten years now. I began my training in an accelerated pre-med program, and have continued both my interest and research in related topics. I only invest in companies after very lengthy deliberation, although am apt to leave the market entirely for periods of time. I have almost exclusively traded in the biotech sector.
PhD in Physics; worked for ten years as a quantitative analyst and software developer for a hedge fund and investment banks.
My experience has taught me to be very sceptical of "analyst opinions" and managed funds in general.
Leonard is an editor of BioTuesdays.com. Before joining the blog, Leonard amassed 36 years of experience as a financial journalist, editor and manager with The Wall Street Journal and Dow Jones News Service, and The Globe and Mail’s Report on Business, where he pioneered the development and launch of the newspaper’s Money & Markets section in the early 1990s. Most recently, he was Canada’s leading biotechnology and healthcare writer, as well as the author of a highly popular stock market blog on globeandmail.com.
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular position. Please click to follow me if you like my work. There’s an option to follow me at the top of my articles. Best functionality of site is on desktop.
OTHER PLACES TO FOLLOW ME:
I’M NOT A FINANCIAL ADVISOR & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;) Investment Philosophy: Understand why you are getting in.
My positions, long or short can change dramatically as new information comes to my attention. All stocks are risky, but, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment.
No payment in any form is accepted for my writing by any company or other party. I only receive that which comes from writing on Seeking Alpha.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)
I am a former hedge fund portfolio manager that trades for my own personal account. I espouse Graham and Dodd/Buffett style investing, always on the lookout for value equities or bonds. A graduate of Northwestern's Kellogg School of Management, I lived in NYC for a decade before relocating with my family to the Charlotte, NC area in 2007.
Currently I am the Chief Analyst at sharpeequities.com.
For more information on my current endeavor, feel free to find me on LinkedIn.
Chicago-based former REIT buy-side analyst looking for mis-priced opportunities both long and short.
Follow me on Twitter @SinglePlurality (I'm so profound!) where I remain critical of Twitter management despite my long position...what can I say?...old habits are hard to break.
Equity Flux offers its clients financial consultancy services. We pride ourselves on our ability to provide you with the latest research, news, views and opinions. We aim to build long term relationships by helping our clients and partners create sustainable value for their own businesses.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
With a focus on out-of-favor equities in the volatile high-technology, biotechnology, and natural resources sectors, we invest in companies with hidden deep value. The fund is led by a veteran researcher, whose core competency is in unraveling murky stories and strategically sifting through fundamentals.
With our experience, we hope to help readers discover alpha in areas most investors are not - or refuse to be - looking.
Investor with more than 5 years experience trading commodities, gold and silver miners, exploration companies, oil and gas, platinum and other hard assets.
The investment style is part contrarian/value and I actively seek investments in distressed sectors.
Engineer by trade and passion. Have worked internationally for over three decades, running my own business. I hold a PhD in engineering, but honestly believe that the school of hard knocks has taught me lessons that are more applicable to my writing here on Seeking Alpha.
My investing interests mostly concern the resource sector, with a focus on precious metals, base metals and energy stocks of all sizes. My research explicitly includes small- and micro-cap juniors, and I try to manage the associated risks in a methodical manner.
I am a simple individual investor who believes that the playing field is level, but may require active management of one's holdings.
I've devised a series of steps that constitute a highly defined covered option strategy that most anyone can follow and that I've described in Option to Profit (2011).
Having retired from a career in Pediatric Dentistry, approximately 10 years ahead of schedule, after spending the previous 10 years working just 2 days each week, I now spend my time trading and alerting others of trading opportunities in large cap positions through the Option to Profit subscription service, a premium subscription service that provides actionable Trading Alerts via text messaging or e-mail at www.optiontoprofit.com. as well as a Web site access only subscription plan.
The Option to Profit subscription service is now in its 4th year.
Now, the Web Access subscription plan is available through Seeking Alpha's "Marketplace." A listing of those articles can be found at https://seekingalpha.com/account/research/subscribe?slug=george-acs
The subscription through Seeking Alpha also includes access to the full Option to Profit web mirror site at http://sa.optiontoprofit.com.
I want you to join me in making your stock portfolio improve the quality of your life. Whatever stage of life you are in, you can make your stocks improve that quality by putting them to work for you.
GuruFundPicks.com offers top buy & sell picks based on the collective or Consensus Picks' of over 330 of our hand-picked top hedge & mutual fund managers, incl. 78 legendary or guru fund managers, 27 of the world's largest or mega funds, 165 sector-focused funds (in gold, biotech, tech, energy, consumer, finance & REITs), 59 billionaires, 54 new masters and 40 tiger, 52 shareholder activist and our Winners Circle Top 100 Performing Hedge Fund Managers (updated quarterly). We offer market-beating tools and services including Consensus Picks' DIY Tools, Top 20 Small-Cap and Top 30 All-Cap Long/Short Newsletters based on the Consensus Picks system, and Trade Alert Services for Self & Auto-Trading. All of our services have beaten market averages by wide margins. See our website GuruFundPicks.com for the latest performance numbers, or contact us at support@GuruFundPicks.com.
The two authors are co-managers of a family partnership long/short equity fund since 2001, that have a successful track record in trading primarily small-cap aggressive growth companies based on a fundamental valuation analysis of current news, including quarter reports, guidance, biotech clinical study results and other news. The junior partner is a self-taught private investor with a Business degree from the New York University's Leonard N. Stern School of Business and the senior partner has an MBA from the University of Virginia Darden School of Business, including prior MS & BS (Engg.) degrees, and with experience in business strategy consulting to large fortune 100 companies.
We are generally sector and market-cap agnostic, identifying opportunities using a 'stock picking' bottom-up, fundamentals-based, valuation-driven approach. However, we find most opportunities in the small-cap space, in technology & healthcare sectors, with some also found often in the consumer, energy & basic materials sectors.
Follow us on Seeking Alpha and Twitter (@GuruFundPicks), and connect with us on LinkedIn (http://www.linkedin.com/in/manishbabla)
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Hilary Kramer is the editor in chief of the subscription newsletters: Game Changers, Breakout Stocks Under $10, High Octane Trader, Absolute Capital Return Portfolio and Inner Circle. For more than a decade, Hilary was the CIO of a $5 billion global private equity fund. She has an MBA from the Wharton School at the University of Pennsylvania and a BS with honors from Wellesley College. She began her Wall Street career as an analyst at Morgan Stanley. Hilary is the author of The Little Book of Big Profits from Small Stocks (Wiley) and Ahead of the Curve: Nine Simple Ways to Create Wealth by Spotting Stock Trends (Free Press). To learn more about Hilary Kramer visit: http://GameChangerStocks.com.
I am a self employed Health care provider, with a private practice specializing in traumatic and sport related musculoskeletal injuries. Since High School I have always had an interest in stocks and have been trading personally on a regular basis. I am not and have never been a stock broker/trader/ or professionally employed in any related financial field. I manage a small professional condo building.
I am marriied with 2 children, I enjoy rigorous exercise and bicycle riding.
TheStreetSweeper recently named Sonya Colberg as Senior Editor. About three years ago, she became senior investigative reporter of TheStreetSweeper, a website devoted to exposing fraud, shenanigans and lousy business practices of public companies. Sonya had worked more than two decades as an editor and reporter for two major newspapers, including the recent Warren Buffett acquisition, Tulsa World. Among others, the Associated Press, Great Plains Journalism Awards, The Gerald Loeb Awards and the Society of Professional Journalists have recognized Sonya’s investigative, feature, health, news and business stories. A fearless investigative reporter, Sonya loves nothing better than calling out the shysters and bumblers who quietly work to separate investors from their hard-earned money.
I am an independent trader. I have been trading my own money for over 20 years.
I am focused on finding growth stocks that are priced like value stocks or stocks that are misunderstood or under followed. Generally, I buy stocks where I feel like my chances of losing money are low, but still offer the possibility of large gains. This almost always leads me to small and microcap cap stocks.
I joined Seeking Alpha to share some of my ideas with others. I hope they are profitable.
Please do your own due diligence and do not blindly buy stocks on Seeking Alpha articles alone (including mine).